Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 6-7
Submit an article Journal homepage
447
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Helicobacter pylori eradication in the Swedish population

Eva DoorakkersUpper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Correspondence[email protected]
View further author information
,
Jesper LagergrenUpper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; ;Division of Cancer Studies, King’s College London, London, UK; View further author information
,
Vijaya Krishna GajulapuriUpper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; View further author information
,
Steven CallensDepartment of Internal Medicine and Infectious Diseases, Ghent University, Ghent, Belgium; View further author information
,
Lars EngstrandCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ;Science for Life Laboratory, Stockholm, SwedenView further author information
&
Nele BrusselaersUpper Gastrointestinal Surgery, Department of Molecular medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; ;Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ;Science for Life Laboratory, Stockholm, SwedenView further author information
Pages 678-685 | Received 21 Dec 2016, Accepted 03 Mar 2017, Published online: 21 Mar 2017

References

  • Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
  • Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.
  • Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299–304.
  • Agreus L, Hellstrom PM, Talley NJ, et al. Towards a healthy stomach? Helicobacter pylori prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterol J. 2016;4:686–696.
  • Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2016; DOI: 10.1136/gutjnl-2016-312288 [Epub ahead of print].
  • Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.
  • Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–1384.
  • Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11:224–230.
  • Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidem Drug Safe. 2007;16:726–735.
  • Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2014;63:1410–1415.
  • Camargo MC, Garcia A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485–495.
  • Akre K, Signorello LB, Engstrand L, et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res. 2000;60:6376–6380.
  • Juul KV, Thomsen OO, Nissen A, et al. National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. Scand J Gastroenterol. 1998;33:928–932.
  • Behandling av Helicobacter pylori-infektioner. Uppsala: Läkemedelsverket; 1995 [cited 2016 Dec 19]. Available from: https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/helicobacterpylori.pdf
  • Zhang YY, Xia HH, Zhuang ZH, et al. Review article: ‘true’ re-infection of Helicobacter pylori after successful eradication–worldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther. 2009;29:145–160.
  • Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011;106:1970–1975.
  • Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2008;13:69–74.
  • Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med. 2009;20:53–57.
  • Chi CH, Lin CY, Sheu BS, et al. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18:347–353.
  • Perri F, Festa V, Clemente R, et al. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96:58–62.
  • Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59:1465–1470.
  • Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488–496.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.